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ity was assessed in terms of convergent validity. RESULTS: 126
subjects returned the ﬁrst questionnaire, of which 113 completed
the second. Women represented 59.9% of the sample, and
respondents’ mean age was 56.8 +/− 18 years. 38.7% of subjects
reported having chronic illness. The number of missing items
from the descriptive EQ-5D (aggregated for both administra-
tions) was 4, representing 0.33% of all responses. Five EQ-VAS
responses were returned incomplete. 97 (85.8%) respondents
reported no change in health in the fortnight between the ﬁrst
and second administration. The Spearman rank coefﬁcients for
these respondents were 0.828 for EQ-5D scores, and 0.815 for
EQ-VAS, respectively (both p < 0.000). The results of the regres-
sion analysis for convergent validity suggested that, together,
EQ-VAS score, self-reported health (5-point Likert scale; poor to
excellent), presence of chronic illness, and receipt of treatment,
explained 66.0% of the variation in EQ-5D scores. CONCLU-
SION: It is concluded that the Welsh version of the EQ-5D has
good acceptability, validity and reliability in measuring health
status in subjects across Wales.
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OBJECTIVES: An understanding of the exchange rate in health
values is a necessary requirement to the transfer of health out-
comes data across national borders. As a preliminary to study-
ing the valuation data for EQ-5D health states in US and Chile
it is useful to establish the comparability in values for self-
reported health in the two countries. METHODS: EQ-5D is a
generic, single index measure of health-related quality of life. It
was included as part of a national valuation study conducted in
the US in 2003 that elicited responses from a subgroup of 1216
Hispanics aged 18 and over. Similar data using EQ-5D was col-
lected in a national survey of health in Chile (n = 4258). All
respondents were assigned to a unique EQ-5D health state
deﬁned by their level of reported problem on the 5 dimensions.
The mean visual analogue scale (VAS) score for each of these
health states was computed from respondents’ rating of their
own health status on a 0–100 scale (EQ-5DVAS). Mean EQ-5DVAS
scores for each available EQ-5D health state were compared
across the 2 country samples. RESULTS: The value of self-
assessed health status was generally higher in the US Hispanic
subgroup than for the same EQ-5D health state in the Chilean
survey with a mean absolute difference of 8.5. A linear regres-
sion model used to examine the relationship between values for
the most prevalent self-assessed health in the two countries took
the form EQ-5DCHILE = 0.773*EQ-5DUS-H + 10.301 CONCLU-
SION: Should this relationship in values for self-classiﬁed EQ-
5D health states prove to be stable, then it could be used as a
conversion factor to estimate values for EQ-5D in Chile from
values obtained from Hispanic respondents in the US national
survey. Data from surveys reporting values for actual health
states appear to be useful in recalibrating scales of value for
hypothetical health states.
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OBJECTIVES: It is unknown whether minimal important dif-
ferences (MID) identiﬁed on generic patient reported outcomes
are consistent across disease states. This research compares
mapped utility instrument MID values within four newly identi-
ﬁed patient groups. METHODS: Retrospective analysis of a 
two-year longitudinal study in a Western US managed care 
population was conducted. Individuals receiving a prescription
for a new disease state in either year were selected. Four major
disease states, each with more than 100 patients reporting a
minimal change in health over the past year on the SF-36 general
health question were included. MID values were calculated for
gains and losses in health on the Brazier, Lundberg, Nichol, and
Shmueli mapped utility instruments. MID values between disease
groups for each instrument were tested with ANOVA. Effect
sizes were compared in accordance to Norman (2001) as a dis-
tribution-based method to determine the MID. RESULTS:
Results are displayed for Brazier’s SF-6D measure as all mapped
utility instruments had similar results. 145, 240, 306, and 150
patients reported a minimal gain or loss in health over the year
when they ﬁlled a new prescription for cardiac disease, COPD,
depression and rheumatoid arthritis, respectively. The reported
mean MID utility change for gains was 0.026, 0.022, 0.019, and
0.018 for each patient group, respectively (P = 0.975). The
reported mean MID utility change for losses was −0.069, −0.045,
−0.055, and −0.028 for each patient group, respectively (P =
0.217). The average effect sizes ranged from 0.133 and 0.194
for gains and from −0.241 and −0.627 for losses. Therefore,
according to Cohen’s classiﬁcation system, the MID values in
gains were not signiﬁcant changes, while those in losses were
considered small. CONCLUSION: This data demonstrates con-
sistent, but small, MID values across various disease groups for
each utility instrument. Researchers should conﬁrm results in
other populations.
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OBJECTIVES: Evaluate the practical and psychometric proper-
ties of the instruments used to measure patient satisfaction with
pharmacist cognitive services, including medication therapy
management and patient counseling. METHODS: After a com-
prehensive literature review, instruments were included based on:
at least one peer-reviewed publication using the instrument, ref-
erence lists, instrument availability, and a focus on pharmacist
cognitive services. The six measurement criteria used were: prac-
tical features (administration time), breadth (multidimensional
construct), depth (ﬂoor and ceiling effects), internal consistency
(coefﬁcient alpha > 0.7) and test-retest reliability (r > 0.7), and
validity. Measurement evaluation was based on McHorney and
Tarlov’s (1995) criteria for evaluation of outcome measurements
and the recent Food and Drug Administration guide on patient
reported outcome measures (2006). RESULTS: Of the 22 instru-
ments identiﬁed, ﬁve were excluded because satisfaction was not
measured as a multidimensional construct. Of the remaining 17
instruments, none met all six study criteria. A majority of the
studies focused on patients’ interaction with the pharmacist in a
community pharmacy setting. Instruments were notable for the
lack of reported psychometric data, especially test-retest relia-
bility, which was reported in only one instrument. Only nine of
17 instruments reported internal consistency measures, but the
nine reporting met study criteria (alpha > 0.7). The series of
instruments developed by MacKeigan and Larson (1989, 1994,
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2002) were supported by adequate reliability data (coefﬁcient
alpha > 0.7) and multiple validation studies. Overall, when data
was available, in a majority of the cases, measures met study
standards. CONCLUSION: Evaluation of patient satisfaction
with pharmacist cognitive services is critical to optimizing
patient care in a clinical or community setting. To accomplish
this, precise and valid measures are vital; however, no one instru-
ment met all criteria. Lack of reported data warrants further
research documenting an instrument’s psychometric properties,
ease of administration, and ability to capture the multidimen-
sional nature of patient satisfaction.
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OBJECTIVES: The US Valuation of the EQ-5D Health States
was conducted to predict US societal preferences for the 243
health states described by the EQ-5D. The model used to gener-
ate these predictions (i.e., the D1 model) addressed a number of
important conceptual and statistical issues. However, it has been
criticized for being too complex and for failing to account for
the non-normal distribution of health state preferences. Further-
more, the model’s developers have been faulted for applying an
arbitrary transformation to the values for worse-than-death
health states prior to estimation. This paper describes the devel-
opment of an improved model for predicting US preferences for
EQ-5D health states. METHODS: Model parameters were esti-
mated using a probability-weighted least absolute deviations esti-
mator. Variance estimation proceeded using a replication-based
jackknife method. The resulting model predictions were con-
trasted with those of the D1 model. The ﬁt of a median model
for data collected in the Measurement and Valuation of Health
study was also studied. RESULTS: When applying no transfor-
mation to the values for states worse than death, the best-ﬁtting
model included only ﬁxed effects for moderate or severe prob-
lems in each of the 5 EQ-5D dimensions and excluded a con-
stant. This speciﬁcation yielded a squared rank correlation
between observed and predicted values of 0.363, a median
absolute error of 0.025, and a rank correlation between median
observed and predicted values of 0.991. The predicted median
preferences ranged from 1.00 for full health to −0.80 for the
worst possible health state. CONCLUSION: The application of
a linear model to the US valuation data cannot be justiﬁed given
the non-normal distribution of health state preferences. A
median model of preferences is superior to other available spec-
iﬁcations. In applications requiring US societal preferences, it is
suggested that the predictions of the model discussed here be
used instead of those of the D1 model.
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OBJECTIVES: Little research concerning to the effect of co-
morbidity on Health Service Utilization was conducted in ﬁeld
of General Practice. We aim to explore the effect of common
chronic diseases on the Health Service Utilization  G
METHODS: Cross-sectional design was conducted. 750 Sample
of patients was obtained via three stages of cluster sampling.
Each patient was asked whether or not he or she contracted fol-
lowing eight common chronic diseases diagnosed by doctor, i.e.,
hypertension, diabetes, heart attack of any category, apoplexy,
asthma or other respiratory disease (COPD), chronic arthritis,
mental disease and other disease lasting over four weeks. Our
research focuses on the relation between common chronic dis-
eases and Health Service Utilization (monthly consultation rate,
annual consultation rate and annual hospitalization rate).
RESULTS: Our research has shown that Health Service Utiliza-
tion of each chronic disease is all higher than reference group.
The overall number of chronic diseases has the linear relation
with annual consultation rate, monthly consultation rate and
annual hospitalization rate separately. Meanwhile, increasing
one type of chronic disease leads to adding additional 8.3 annual
consultation rat; the OR value of annual hospitalization rate is
1.786 which hints that increase one type of chronic diseases will
induce more 78.6% relative risk of possible hospitalization rate.
Furthermore, the other seven types of chronic diseases, except
for apoplexy, have a positive linear relation with annual consul-
tation rate; diabetes, cardiopathy and apoplexy have respectively
positive linear relation with annual hospitalization rate. CON-
CLUSION: Our systematical approach addressed the scarcity
that most researches in China only focus on single disease, espe-
cially in the ﬁeld of General Practice Research. Our research sup-
ports the assumption that common chronic diseases can be taken
as the predicting factor for risk adjustment model and can
predict health services utilization.
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OBJECTIVES: Up to date in mainland China, no data has been
shown the relationship between health-related quality of life
(HRQOL) and health services utilization. This study is aim to
conﬁrm the hypothesis that the scale-score of the SF-36 is in
linear relationship with Health Services Utilization, and to quan-
tify its linear relationship after the conﬁrmation of above hypoth-
esis. METHODS: Cross-sectional design was conducted. Sample
was obtained via three stages of cluster sampling. We use both
electronic version (based on QL-Recorder) and paper version of
SF-36. Data process was conducted by the structured multiphase
regression model. RESULTS: Firstly, in terms of monthly con-
sultation rate, the scale-score of the SF-36 separately intercepted
5.1% contribution. Secondly, with respect to annual consulta-
tion rate, the scale-score of the SF-36 solely explained 2.7% con-
tribution. Thirdly, referring to annual hospitalization rate, the
scale-score of the SF-36 explained 4.7%. Besides, our research
induces that there was gender difference of the scale-score of the
SF-36 on Health Service Utilization, namely, the female are
higher than the male. CONCLUSION: Our research proved, for
the ﬁrst time in Mainland China, that the hypothesis on linear
relation between the scale-score of the SF-36 and Health Service
Utility. We further calculated in quantiﬁcation, the separate con-
tribution rate of the scale-score of the SF-36 to Health Service
Utilization.
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